Aquestive Therapeutics, Inc. (AQST)

Aquestive Therapeutics Statistics

Total Valuation

AQST has a market cap or net worth of $279.81 million. The enterprise value is $246.26 million.

Market Cap	279.81M
Enterprise Value	246.26M

Important Dates

The next confirmed earnings date is Monday, May 12, 2025, after market close.

Earnings Date	May 12, 2025
Ex-Dividend Date	n/a

Share Statistics

AQST has 98.87 million shares outstanding. The number of shares has increased by 41.58% in one year.

Current Share Class	98.87M
Shares Outstanding	98.87M
Shares Change (YoY)	+41.58%
Shares Change (QoQ)	+0.13%
Owned by Insiders (%)	5.82%
Owned by Institutions (%)	47.50%
Float	93.12M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	4.26
Forward PS	5.22
PB Ratio	-4.65
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	4.28
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 4.68

Current Ratio	4.68
Quick Ratio	4.18
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-1.83

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-24.22%
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	-37.27%
Revenue Per Employee	$405,359
Profits Per Employee	-$310,824
Employee Count	142
Asset Turnover	0.72
Inventory Turnover	2.79

Taxes

Income Tax	-14,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -19.60% in the last 52 weeks. The beta is 2.02, so AQST's price volatility has been higher than the market average.

Beta (5Y)	2.02
52-Week Price Change	-19.60%
50-Day Moving Average	2.80
200-Day Moving Average	3.80
Relative Strength Index (RSI)	51.03
Average Volume (20 Days)	1,143,553

Short Selling Information

The latest short interest is 9.87 million, so 9.98% of the outstanding shares have been sold short.

Short Interest	9.87M
Short Previous Month	10.02M
Short % of Shares Out	9.98%
Short % of Float	10.60%
Short Ratio (days to cover)	7.10

Income Statement

In the last 12 months, AQST had revenue of $57.56 million and -$44.14 million in losses. Loss per share was -$0.51.

Revenue	57.56M
Gross Profit	39.69M
Operating Income	-30.77M
Pretax Income	-25.76M
Net Income	-44.14M
EBITDA	-30.03M
EBIT	-30.77M
Loss Per Share	-$0.51

Balance Sheet

The company has $71.55 million in cash and $38.00 million in debt, giving a net cash position of $33.54 million or $0.34 per share.

Cash & Cash Equivalents	71.55M
Total Debt	38.00M
Net Cash	33.54M
Net Cash Per Share	$0.34
Equity (Book Value)	-60.16M
Book Value Per Share	-0.66
Working Capital	69.36M

Cash Flow

In the last 12 months, operating cash flow was -$35.76 million and capital expenditures -$159,000, giving a free cash flow of -$35.92 million.

Operating Cash Flow	-35.76M
Capital Expenditures	-159,000
Free Cash Flow	-35.92M
FCF Per Share	-$0.36

Margins

Gross margin is 68.95%, with operating and profit margins of -53.46% and -76.68%.

Gross Margin	68.95%
Operating Margin	-53.46%
Pretax Margin	-76.70%
Profit Margin	-76.68%
EBITDA Margin	-52.17%
EBIT Margin	-53.46%
FCF Margin	n/a

Dividends & Yields

AQST does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-41.58%
Shareholder Yield	-41.58%
Earnings Yield	-15.77%
FCF Yield	-12.84%

Analyst Forecast

The average price target for AQST is $11.40, which is 302.83% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$11.40
Price Target Difference	302.83%
Analyst Consensus	Strong Buy
Analyst Count	5
Revenue Growth Forecast (5Y)	35.05%
EPS Growth Forecast (5Y)	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

AQST has an Altman Z-Score of -3.4 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-3.4
Piotroski F-Score	3